| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Association between EGFR mutation and ageing, history of pneumonia and gastroesophageal reflux disease among patients with advanced lung cancer
|
Choi, Won-Il
|
|
2019
|
122 |
C |
p. 101-108
|
article
|
| 2 |
Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CeFCiD): an open-label phase II randomised trial (AIO/IAG-KHT trial 1108)
|
Klinghammer, K.
|
|
2019
|
122 |
C |
p. 53-60
|
article
|
| 3 |
Clonal diversity of MYC amplification evaluated by fluorescent in situ hybridisation and digital droplet polymerase chain reaction in oesophagogastric cancer: Results from a prospective clinical trial screening programme
|
Davidson, Michael
|
|
2019
|
122 |
C |
p. 12-21
|
article
|
| 4 |
Deep and sustained radiological response after MEK-RAF inhibition in HRAS mutant apocrine carcinoma of the scalp
|
Scaranti, Mariana
|
|
2019
|
122 |
C |
p. 9-11
|
article
|
| 5 |
EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease
|
Levy, Antonin
|
|
2019
|
122 |
C |
p. 109-114
|
article
|
| 6 |
Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
|
Michot, J.M.
|
|
2019
|
122 |
C |
p. 72-90
|
article
|
| 7 |
Outcome of adolescent patients with acute lymphoblastic leukaemia aged 10–14 years as compared with those aged 15–17 years: Long-term results of 1094 patients of the AIEOP-BFM ALL 2000 study
|
Testi, Anna Maria
|
|
2019
|
122 |
C |
p. 61-71
|
article
|
| 8 |
Preclinical models of breast cancer: Two-way shuttles for immune checkpoint inhibitors from and to patient bedside
|
Abdel-Aziz, Amal Kamal
|
|
2019
|
122 |
C |
p. 22-41
|
article
|
| 9 |
The significance of tumour deposits in rectal cancer after neoadjuvant therapy: a systematic review and meta-analysis
|
Lord, A.C.
|
|
2019
|
122 |
C |
p. 1-8
|
article
|
| 10 |
The transformation of radiation oncology using real-time magnetic resonance guidance: A review
|
Hall, William A.
|
|
2019
|
122 |
C |
p. 42-52
|
article
|
| 11 |
UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2–positive subgroup
|
D'Hondt, Véronique
|
|
2019
|
122 |
C |
p. 91-100
|
article
|
Journal description